Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.65 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.65 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064682 | 0.81 | GABRA1 (0.77) | GABRA1GABRB2ELANECTSG | |
| SCHEMBL864085 | 0.80 | GABRA1 (1.00) | GABRA1GABRB2ELANECTSGTSHR | |
| SCHEMBL7064652 | 0.77 | GABRA1 (0.83) | GABRA1GABRB2ELANECTSGTSHR | |
| SCHEMBL10595735 | 0.75 | GABRA1 (0.67) | GABRA1GABRB2ELANECTSGTSHR | |
| SCHEMBL23964427 | 0.74 | CA2 (0.50) | GABRA1GABRB2HTR1AHTR6HTR1D | |
| Hydrochloric Acid SCHEMBL11572646 | 0.74 | ALDH1A1 (0.55) | GABRA1GABRB2TSHRDRD3 | |
| SCHEMBL29324601 | 0.73 | KCNH2 (0.49) | GABRA1GABRB2HTR1AOPRM1OPRK1 | |
| SCHEMBL14551465 | 0.73 | GABRA1 (0.83) | GABRA1GABRB2ELANECTSGTSHR | |
| SCHEMBL23926336 | 0.73 | ERN1 (0.44) | GABRA1GABRB2HTR1AHTR6HTR1D | |
| SCHEMBL30118893 | 0.73 | ERN1 (0.44) | GABRA1GABRB2HTR1AHTR6HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | GABRA1 3643/4885GABRB2 2413/4885HTR1A 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.